Oct. 13, 2011
Emory Vaccine Center Partners With Global Initiative to Boost Vaccine Research and Development
European Union and partners contribute 41 million euros in funding for 13-nation vaccine program
A team of 42 universities and research institutions in 13 countries will work to accelerate human vaccine development through a new collaborative research program named Advanced Immunization Technologies (ADITEC).
The partnership, led by Novartis, was launched Oct. 1 with 30 million euros in funding over five years from the European Union and 11 million euros in co-funding from collaborating organizations. ADITEC will develop new technologies and a robust platform for innovation in the next generation of human vaccines.
As a research partner, the Emory Vaccine Center — one of the largest groups of academic vaccine scientists in the world — will contribute key expertise in vaccine research and development. Emory Vaccine Center Director Rafi Ahmed, PhD, is a world-renowned expert in immune memory and vaccine protective immunity. Bali Pulendran, PhD, director of Emory's recently established Center for Systems Vaccinology, will contribute his expertise in innate immunity and systems biology -- identifying all aspects of the immune system, including genomic signatures that contribute to vaccine effectiveness.
"Tremendous progress has been made in vaccine development over the past several decades," says Ahmed, who is also a Georgia Research Alliance Eminent Scholar. "We have the opportunity to move forward rapidly and dramatically with vaccines that are effective against the world¿s most challenging and emerging diseases. This international effort will bring together the most innovative research and create critical synergies."
ADITEC comprises a team of competitive European universities and research institutions and leading U.S. centers in vaccine development, systems biology and vaccine adjuvants. The project is reinforced by a number of key European industries, both large pharmaceutical and smaller biotechnology companies, focusing on specific innovative technologies that allow development and manufacture of better and safer vaccines. In addition, the World Health Organization is supporting the project as a senior partner, ensuring that cross cutting global health aspects of vaccines are duly considered.
The research partnership covers a wide range of crucial aspects of vaccination, from basic research and new technologies to clinical trials and public health. The high- impact project is expected to lead to improved potency and safety of vaccines and their components; novel routes and devices of administration; optimized vaccination strategies; optimized formulations and vaccination methods for different age groups; better insight in the effects of gender, chronic diseases and genetic variation on vaccination; and widespread knowledge about the available new technologies.
ADITEC is coordinated by Rino Rappuoli and Donata Medaglini of Sclavo Vaccines Association (SVA) in Siena, Italy.
Sclavo Vaccines Association, Italy
Statens Serum Institut, Denmark
St. George University of London, United Kingdom
Max Planck Institute for Infection Biology, Germany
University of Siena, Italy
Institute Pasteur, France
University of Oxford, United Kingdom
University of Geneva, Switzerland
Novartis Vaccines and Diagnostics s.r.l., Italy
University of Goteborg, Sweden
Leiden University and Medical Centre, The Netherlands
Emory University, Atlanta, USA
Tuberculosis Vaccine Initiative, The Netherlands
Institute for Biomedical Aging Research, Austria
Infectious Disease Research Institute Seattle, USA
Utrecht University, The Netherlands
Fondazione Humanitas per la Ricerca, Italy
Fondazione per l'Istituto di Ricerca in Biomedicina, Switzerland
Istituto Superiore di Sanità, Italy
Kings College London, United Kingdom
World Health Organization, Switzerland
French Atomic Energy, France
Institut de Biologie et Chimie des Protéines, France
Erasmus Medical Center, The Netherlands
ALTA s.r.l.u, Italy
Medicine in need, France
deCODE Genetics, Iceland
Sigmoid Pharma, Ireland
Pevion Biotech, Switzerland
Duotol AB, Sweden
Crossbeta Biosciences, The Netherlands
Xbrane Bioscience AB, Sweden
Bioneedle Group, The Netherlands
Novartis Vaccines Institute for Global Health s.r.l, Italy
National Institute for Biological Standards and Control, United Kingdom
Seattle Biomedical Research Institute, USA
Imperial College London, UK
Originally posted Oct. 11, 2011